Results 91 to 100 of about 52,166 (258)
Obesity, EarlyView.ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo +4 more
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective This study examined racial differences in weight loss and clinical response to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy among adults with obesity using real‐world data. Methods We retrospectively analyzed our institution's Research Data Warehouse (RDW) containing deidentified data from electronic health records ...
Jordan H. Mallette +4 more
wiley +1 more source
Bariatric surgery and diabetes
Indian Journal of Endocrinology and Metabolism, 2012 Obesity is a relatively new and serious world-wide epidemic. Obesity is a stronger predictor in mortality than either poverty or smoking, and obesity is also now more prevalent than malnutrition. The prevalence of obesity continues to increase, ironically, the rate of increase of obesity is highest amongst the morbidly obesity. Obesity is the result of
openaire +3 more sources
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
Obesity, EarlyView.ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin +4 more
wiley +1 more source
Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency
Obesity, EarlyView.ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak +2 more
wiley +1 more source
What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?
The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart +3 more
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies.
Janice Bidesie, Erik Oudman
wiley +1 more source
Trends in Diagnosing Obesity: The CALOR Study
Obesity, EarlyView.Data from the CALOR study suggest that in people with elevated BMI in the US and Japan, there is underdiagnosis of obesity and a high prevalence of diseases interrelated to obesity. ABSTRACT Objective This study aimed to describe characteristics of people with elevated BMI by presence versus absence of obesity diagnosis and trends over time.
Deborah B. Horn +4 more
wiley +1 more source